RESUMEN
OBJECTIVE: Aggressive fibromatosis (AF), also called desmoid tumor, is an uncommon soft-tissue neoplasm. Characteristically, it expands locally without metastatic potential. However, its tendency of relapse after curative resections has been well documented. Effective treatment options have been limited and there is a clear need for novel treatment strategies. METHODS: We used combination therapy including multikinase tyrosine kinase inhibitor for treating AF. RESULTS: We presented a case of an extra-abdominal AF who was successfully treated with meloxicam and sorafenib combination in our clinic. She tolerated this therapy well with only mild side effects. To our knowledge, this is the first case report of an extra-abdominal AF with a major partial response to sorafenib and meloxicam combination. CONCLUSION: Due to the favorable toxicity profile of sorafenib and meloxicam, this combination might be an effective treatment option for patients with locally aggressive and inoperable AF.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Fibromatosis Agresiva/tratamiento farmacológico , Neoplasias de los Músculos/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Femenino , Fibromatosis Agresiva/diagnóstico por imagen , Fibromatosis Agresiva/patología , Humanos , Pierna/patología , Imagen por Resonancia Magnética/métodos , Meloxicam/administración & dosificación , Neoplasias de los Músculos/diagnóstico por imagen , Neoplasias de los Músculos/patología , Recurrencia Local de Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/patología , Inhibidores de Proteínas Quinasas/administración & dosificación , Sorafenib/administración & dosificación , Resultado del TratamientoRESUMEN
The incidence of deep vein thrombosis (DVT) and pulmonary embolism has been increasing in the elderly because of hypercoagulability associated with aging. Age has also been identified as an independent risk factor for bleeding complications related to anticoagulation therapy. Inferior vena cava filters could be used as alternatives to anticoagulant therapy for the prevention of pulmonary embolism when anticoagulation is either contraindicated or ineffective. Here, we report two geriatric patients who had documented acute DVT and in whom inferior vena caval filter was used because of the patients have a contraindication to use an anticoagulation.